Use of intravenous magnesium sulfate in addition to standard first-line treatment with inhaled/nebulised short-acting beta 2 agonist and systemic steroids in the management of acute asthma exacerbations in children: a systematic review and meta-analyses of randomised controlled trials.
Archives of Disease in Childhood · 2025-06-26 · Meta-analysis
Abstract
BACKGROUND: The role of intravenous magnesium sulfate in asthma exacerbation is unclear. AIMS: To determine the efficacy and safety of intravenous magnesium sulfate in managing asthma exacerbation in children. METHODS: We searched MEDLINE, EMBASE, CINAHL, the Cochrane Central Register of Controlled Trials and the Web of Science up to May 2024. We included randomised controlled trials and followed the international guidelines for conducting systematic reviews. Outcomes included morbidity, escalation of care, length of hospital stay, lung functions, adverse events, and mortality. RESULTS: Nine studies (total participants=473) were included. Hospitalisation rate and the need for non-invasive ventilation were less among the intravenous magnesium sulfate group (mean difference (MD)=0.70, 95% CI 0.54 to 0.90, I2 7%, n=115) and (risk ratio (RR)=0.17, 95% CI 0.15 to 0.54, p=0.003, n=143), respectively. Asthma severity scores (MD=-0.18, 95% CI -1.35 to 0.98, I2 2%, n=115), length of hospital stay (MD=-78.86, 95% CI -200.37 to 42.66, I2 99%, n=284) and the need for invasive ventilation (RR=0.35, 95% CI 0.11 to 1.17, I2 0%, n=237) were similar. There was no difference in the Paediatric Intensive Care Unit (PICU) admission rate (p=0.43 n=61). Peak expiratory flow improved in the intravenous magnesium group (p<0.001, n=20). No serious adverse events were reported. CONCLUSION: We found low-certainty evidence that intravenous magnesium sulfate results in a lower hospitalisation rate and less need for non-invasive ventilation. Asthma scores, PICU admission, invasive ventilation and length of hospital stay were similar. While the evidence base is weak, the favourable safety profile suggests that intravenous magnesium sulfate can be considered a treatment for asthma exacerbations. PROSPERO REGISTRATION NUMBER: CRD42023405261.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
CPAP & NIV · Mechanical ventilation · Children · Other drugs · Magnesium · Mortality & survival
Related articles
- Second-line treatment option for children aged 18 years and under with an acute severe asthma exacerbation: a systematic review and meta-analysis of randomised controlled trials. (Arch Dis Child, 2025)
- Effect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial. (JAMA, 2020)
- AARC and PALISI Clinical Practice Guideline: Pediatric Critical Asthma. (Respir Care, 2025)
- The association of prehospital systemic corticosteroids with emergency department and in-hospital outcomes for patients with asthma exacerbations. (Acad Emerg Med, 2024)
- Comparison of positive expiratory pressure device versus non-invasive ventilation on outcomes in acute exacerbation of chronic obstructive pulmonary disease in the emergency department. (BMC Emerg Med, 2025)
- Effectiveness of Intravenous and Nebulized MgSO4 in Children with Asthma Exacerbation: A Systematic Review and Meta-Analysis of Clinical Trials. (Children (Basel), 2025)